trending Market Intelligence /marketintelligence/en/news-insights/trending/qGF6hpamslNkeglE4-0jAQ2 content esgSubNav
In This List

Sumitomo fails to reach agreement to acquire Cynata Therapeutics


Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises

Sumitomo fails to reach agreement to acquire Cynata Therapeutics

Sumitomo Dainippon Pharma Co. Ltd. failed to reach an agreement on terms to acquire stem cell technology company Cynata Therapeutics Ltd.

The parties have withdrawn from the acquisition discussions after failing to arrive at a deal.

The Osaka, Japan-based drugmaker previously offered to acquire Australia's Cynata for A$2 per share in cash under a scheme of agreement.

The offer, made in July, valued the stem cell and regenerative medicines company at about A$203.8 million.

Sumitomo manufactures and sells pharmaceuticals, food ingredients and additives, veterinary medicines, diagnostics and other products.

Cynata, which offers a mesenchymal stem cell technology, is developing its lead product candidate CYP-001 as a treatment for graft versus host disease.